FDA wants MRI contrast agent warning

May 23, 2007

The U.S. Food and Drug Administration wants a warning printed on the labels of all gadolinium-based magnetic resonance imaging contrast agents.

The requested boxed warning would state patients with severe kidney insufficiency who receive the chemicals used to enhance the quality of MRI images are at risk of developing a debilitating and a potentially fatal disease known as nephrogenic systemic fibrosis, or NSF.

In addition, the FDA wants the warning to state that patients just before or just after liver transplantation, or those with chronic liver disease, are also at risk.

Gadolinium-based contrast agents are commonly used to improve the visibility of internal structures when patients undergo an MRI. Reports have identified the development of NSF following single and multiple administrations of the gadolinium-based contrast agents.

Copyright 2007 by United Press International

Explore further: Major review to help doctors, patients and public make informed decisions about the use of statins

Related Stories

Have we misunderstood post-traumatic stress disorder?

August 22, 2016

In understanding war-related post-traumatic stress disorder, a person's cultural and professional context is just as important as how they cope with witnessing wartime events, which could change the way mental health experts ...

Hidden stroke victims: The young

September 1, 2016

The headaches were excruciating and wouldn't go away. Her doctor said they were migraines. Then, one morning a few weeks later, Jamie Hancock stood up from the couch and discovered she couldn't move the right side of her ...

Recommended for you


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.